A remarkable news story just came to light on Wednesday. As John Price, president and CEO of Houston-based Greffex Inc., told the Houston Business Journal that his company finished creating a coronavirus vaccine.
And the article states: “Greffex’s treatments use adenovirus-based vector vaccines, which are used to target various kinds of infectious diseases and cancers, according to research published in the peer reviewed journal Human Vaccines & Immunotherapeutics.”
Price added, “The trick in making a vaccine is can you scale the vaccine that you’ve made to be able to make a certain number of doses, can you test the vaccine quickly and efficiently and then can you get it into patients – and that’s where we have an edge as well on the other companies that are out there.”
While The New York Post printed: “If the vaccine wins government approval, Greffex will give it away for free to the hardest-hit countries.”
The company’s web site reads:
GreVac(TM) vaccines are based upon GREFFEX’s proprietary GreGT Genetic Engineering Technology as a fast and flexible plug-and-play vaccine architecture of fully deleted helper virus- independent adenoviral vectors of rare serotypes. The proprietary GreGT platform has been built upon two independently modifiable components to provide broad gene transfer applications.
The GreVac(TM) system incorporates versatility and speed to complement and ultimately change the present paradigm of immune protection against infectious diseases with a high eruption potential from the stockpiling of potential vaccine candidates to the just-in-time production of specific vaccines.
Beyond that, researchers from The University of Texas at Austin and the National Institutes of Health announced they had created the first 3D atomic scale map of the spike protein, the part of the coronavirus that infects human cells. While they indicated, “The atomic-level detail will enable the design and screening of small molecules with fusion-inhibiting potential. This information will support precision vaccine design and discovery of anti-viral therapeutics, accelerating medical countermeasure development.”
Lead researcher on the team Jason McLellan asserted: “As soon as we knew this was a coronavirus, we felt we had to jump at it because we could be one of the first ones to get this structure. We knew exactly what mutations to put into this, because we’ve already shown these mutations work for a bunch of other coronaviruses.”
As University of Texas’ News told, “Next, McLellan’s team plans to use their molecule to pursue another line of attack against the virus that causes COVID-19, using the molecule as a ‘probe’ to isolate naturally produced antibodies from patients who have been infected with the novel coronavirus and successfully recovered. In large enough quantities, these antibodies could help treat a coronavirus infection soon after exposure. For example, the antibodies could protect soldiers or health care workers sent into an area with high infection rates on too short notice for the immunity from a vaccine to take effect.”
This sounds like a breath of fresh air to people all around the world.